Drug‐Eluting Stents: A Mechanical and Pharmacologic Approach to Coronary Artery Disease
暂无分享,去创建一个
P. Dobesh | Zachary A. Stacy | Paul P Dobesh | Jason M Enders | Zachary A Stacy | Alexander J Ansara | A. J. Ansara
[1] T. Meerloo,et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. , 1997, Transplantation.
[3] M. Eisenberg,et al. Coated Stents for the Prevention of Restenosis: Part II , 2002, Circulation.
[4] M. Schreier,et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.
[5] P. Serruys,et al. Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) Trial , 2002, Circulation.
[6] R. Pakala,et al. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. , 1997, Circulation.
[7] L. Wallentin,et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. , 2002, Journal of the American College of Cardiology.
[8] A. Kastrati,et al. Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial , 2001, Circulation.
[9] W. Siegenthaler,et al. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.
[10] R. Alexander,et al. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. , 1991, Journal of the American College of Cardiology.
[11] M. Leon,et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.
[12] M. Hooks. Tacrolimus, a New Immunosuppressant—A Review of the Literature , 1994, The Annals of pharmacotherapy.
[13] Larry S. Dean,et al. Intracoronary Stenting for Acute and Threatened Closure Complicating Percutaneous Transluminal Coronary Angioplasty , 1992, Circulation.
[14] H Sack,et al. [Catheter-based radiotherapy to inhibit restenosis after coronary stenting]. , 1998, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].
[15] A. Zalewski,et al. Transforming Growth Factor-β1 Expression and Myofibroblast Formation During Arterial Repair , 1996 .
[16] P. Serruys,et al. Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries , 2003, Circulation.
[17] U. Ikeda,et al. Acute platelet inhibition with abciximab does not reduce in-stent restenosis. , 2000, Circulation.
[18] A. Marcus,et al. Thrombosis and Inflammation as Multicellular Processes: Significance of Cell-Cell Interactions , 1995, Thrombosis and Haemostasis.
[19] J. Badimón,et al. Rapamycin inhibits vascular smooth muscle cell migration. , 1996, The Journal of clinical investigation.
[20] B R Goldspiel,et al. Paclitaxel (Taxol) , 1994, Pharmacotherapy.
[21] S. Schwartz,et al. Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery , 1985, Circulation research.
[22] F Joffre,et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.
[23] R. Virmani,et al. Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.
[24] P. Serruys,et al. Sirolimus-Eluting Stent Implantation in ST-Elevation Acute Myocardial Infarction: A Clinical and Angiographic Study , 2003, Circulation.
[25] Marcus Aj. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. , 1994 .
[26] 鈴木 健. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model , 2003 .
[27] M. Hadamitzky,et al. Influence of lesion length on restenosis after coronary stent placement. , 1999, The American journal of cardiology.
[28] P. Serruys,et al. Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up , 2002, Circulation.
[29] S. Silber,et al. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.
[30] P. Libby,et al. Inflammation and thrombosis: the clot thickens. , 2001, Circulation.
[31] AlbertSchömig,et al. Vessel Size and Long-Term Outcome After Coronary Stent Placement , 1998 .
[32] S. Marx,et al. Bench to bedside: the development of rapamycin and its application to stent restenosis. , 2001, Circulation.
[33] M. Hadamitzky,et al. Vessel size and long-term outcome after coronary stent placement. , 1998, Circulation.
[34] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[35] J. Spinelli,et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. , 1999, The New England journal of medicine.
[36] N. Weissman,et al. Paclitaxel Coating Reduces In-Stent Intimal Hyperplasia in Human Coronary Arteries: A Serial Volumetric Intravascular Ultrasound Analysis From the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT) , 2003, Circulation.
[37] Rossella Fattori,et al. Drug-eluting stents in vascular intervention , 2003, The Lancet.
[38] C. Vassanelli,et al. [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[39] P. Fitzgerald,et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. , 2000, Circulation.
[40] P. Teirstein,et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. , 2001, The New England journal of medicine.
[41] Patrick W Serruys,et al. New frontiers in cardiology: drug-eluting stents: Part I. , 2003, Circulation.
[42] C. Di Mario,et al. First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome , 2002, Circulation.
[43] M. Eisenberg,et al. Coated stents for the prevention of restenosis: Part I. , 2002, Circulation.
[44] P. Fitzgerald,et al. Novel Drug-Delivery Stent: Intravascular Ultrasound Observations From the First Human Experience With the QP2-Eluting Polymer Stent System , 2001, Circulation.
[45] I. Palacios,et al. Time course and mechanism of early luminal diameter loss after percutaneous transluminal coronary angioplasty. , 1995, The American journal of cardiology.
[46] The Esprit investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial , 2000, The Lancet.
[47] A. N. Mooss,et al. Restenosis, the Achilles' Heel of Coronary Angioplasty , 1998, Pharmacotherapy.
[48] J. Isner,et al. Expression of gax, a Growth Arrest Homeobox Gene, Is Rapidly Down-regulated in the Rat Carotid Artery during the Proliferative Response to Balloon Injury (*) , 1995, The Journal of Biological Chemistry.
[49] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[50] S Marx,et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. , 1999, Circulation.
[51] Elazer R. Edelman,et al. Drug-Eluting Stents in Preclinical Studies: Recommended Evaluation From a Consensus Group , 2002, Circulation.
[52] A. Becker,et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. , 1998, Circulation.
[53] L Chiariello,et al. A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. , 1997, The New England journal of medicine.
[54] A. Heldman,et al. Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial , 2004, Circulation.
[55] P. Teirstein,et al. Restenosis After Placement of Palmaz‐Schatz Stents in Native Coronary Arteries: Initial Results of a Multicenter Experience , 1992, Circulation.
[56] Patrick W Serruys,et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. , 2003, Journal of the American College of Cardiology.
[57] W Siegenthaler,et al. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. , 1987, The New England journal of medicine.
[58] A. Baumbach,et al. Stent‐based antirestenotic coatings (sirolimus/paclitaxel) , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[59] F. Crea,et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. , 1998, The American journal of cardiology.
[60] P. Teirstein,et al. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. , 1999, Circulation.
[61] Mary E. Russell,et al. TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.
[62] William Wijns,et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.
[63] P. Serruys,et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. , 2003, Journal of the American College of Cardiology.
[64] E. Topol,et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.
[65] F. Zijlstra,et al. Sirolimus-eluting coronary stents. , 2004, The New England journal of medicine.
[66] A. Küttner,et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.
[67] Patrick W Serruys,et al. Fate of side branches after coronary arterial sirolimus-eluting stent implantation. , 2002, The American journal of cardiology.
[68] S. Marx,et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. , 1995, Circulation research.
[69] Jeffrey J. Popma,et al. Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2001, Circulation.
[70] Julio C. Palmaz,et al. Clinical Experience With the Palmaz‐Schatz Coronary Stent: Initial Results of a Multicenter Study , 1991, Circulation.
[71] J. Isner,et al. The biology of restenosis. , 1997, Progress in cardiovascular diseases.
[72] E. Tuzcu,et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.
[73] P. Bernatchez,et al. Estrogen Regulation of Endothelial and Smooth Muscle Cell Migration and Proliferation: Role of p38 and p42/44 Mitogen-Activated Protein Kinase , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[74] E. Topol. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.
[75] J. Krieger,et al. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. , 1994, The Journal of clinical investigation.
[76] W Rutsch,et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.
[77] Muzaffer Degertekin,et al. TAXUS III Trial: In-Stent Restenosis Treated With Stent-Based Delivery of Paclitaxel Incorporated in a Slow-Release Polymer Formulation , 2003, Circulation.
[78] R. Virmani,et al. Oral Everolimus Inhibits In-Stent Neointimal Growth , 2002, Circulation.
[79] J. Brophy. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. , 2000, The New England journal of medicine.
[80] E. Topol,et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. , 2001, The New England journal of medicine.
[81] Levon M Khachigian,et al. Coronary In-stent Restenosis: Current Status and Future Strategies , 2022 .
[82] R E Vlietstra,et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. , 1984, The American journal of cardiology.
[83] Richard J. Jones. Heart Disease: A Textbook of Cardiovascular Medicine , 1980 .
[84] M. Bertrand,et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.
[85] E. Vasquez. Sirolimus: a new agent for prevention of renal allograft rejection. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[86] N. Kipshidze,et al. Estrogen‐eluting, phosphorylcholine‐coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[87] T. Springer,et al. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. , 1996, Blood.
[88] P. Fitzgerald,et al. 7-Hexanoyltaxol–Eluting Stent for Prevention of Neointimal Growth: An Intravascular Ultrasound Analysis From the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE) , 2002, Circulation.
[89] Carl J Pepine,et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.
[90] M. Leon,et al. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future. , 2003, American heart journal.
[91] P. Serruys,et al. Late coronary occlusion after intracoronary brachytherapy. , 1999, Circulation.
[92] J. Miano,et al. Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury. A putative in vivo mechanism for autocrine growth. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[93] S. Schwartz,et al. Production of transforming growth factor beta 1 during repair of arterial injury. , 1991, The Journal of clinical investigation.
[94] M. Bennett,et al. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. , 2001, Pharmacology & therapeutics.
[95] P. Teirstein,et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.
[96] P. Serruys,et al. Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2003, Circulation.
[97] M. Mann,et al. Cell cycle progression: new therapeutic target for vascular proliferative disease. , 1998, Circulation.
[98] F. Fernández‐Avilés,et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. , 1999, Journal of the American College of Cardiology.
[99] P. Lund,et al. Human Protein Disulfide Isomerase Functionally Complements a dsbA Mutation and Enhances the Yield of Pectate Lyase C in Escherichia coli(*) , 1995, The Journal of Biological Chemistry.
[100] H Yokoi,et al. Three-year follow-up after implantation of metallic coronary-artery stents. , 1996, The New England journal of medicine.
[101] R. Califf,et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial , 1999, The Lancet.
[102] P. Serruys,et al. Angiographic Findings of the Multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): Sirolimus-Eluting Stents Inhibit Restenosis Irrespective of the Vessel Size , 2002, Circulation.
[103] M. Hadamitzky,et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.
[104] E. Lakatta,et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. , 1995, The Journal of clinical investigation.
[105] J. Gunn,et al. Angiopeptin-eluting stents: observations in human vessels and pig coronary arteries. , 2002, The Journal of invasive cardiology.
[106] M. Tendera,et al. Local Delivery of Enoxaparin to Decrease Restenosis After Stenting: Results of Initial Multicenter Trial: Polish-American Local Lovenox NIR Assessment Study (The POLONIA Study) , 2001, Circulation.
[107] Benno J. Rensing,et al. Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.
[108] B. Zinman,et al. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. , 2004, Diabetes care.
[109] Ousa,et al. A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .
[110] M. Nobuyoshi,et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. , 1988, Journal of the American College of Cardiology.
[111] V. Rajagopal,et al. Coronary restenosis: a review of mechanisms and management. , 2003, The American journal of medicine.
[112] Gregg W. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease , 2004 .
[113] Janita F. J. Vos,et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. , 2001, European heart journal.
[114] P. Tsao,et al. Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.
[115] M. Baggiolini,et al. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[116] J. Dutcher,et al. 20th‐Century Advances in Drug Therapy in Oncology—Part II , 2000, Journal of clinical pharmacology.
[117] N. Weissman,et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. , 2003, The New England journal of medicine.
[118] S. Pocock,et al. A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .
[119] M. Leon,et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. , 1998, Journal of the American College of Cardiology.
[120] C. Di Mario,et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. , 1998, Journal of the American College of Cardiology.
[121] C. Vrints,et al. Study of antirestenosis with the BiodivYsio dexamethasone‐eluting stent (STRIDE): A first‐in‐human multicenter pilot trial , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[122] Seung‐Jung Park,et al. Intravascular ultrasound assessment of patterns of arterial remodeling in the absence of significant reference segment plaque burden in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.
[123] H. Gold,et al. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. , 2002, Journal of the American College of Cardiology.
[124] R. Califf,et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. , 2002, JAMA.
[125] M. Leon,et al. Intravascular ultrasound insights into mechanisms of stenosis formation and restenosis. , 1997, Cardiology clinics.
[126] M. Savage,et al. Restenosis after coronary angioplasty: A multilvariate statistical model to relate lesion and procedure variables to restenosis☆ , 1991 .
[127] M. Leon,et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. , 1995, Journal of the American College of Cardiology.
[128] A. Kastrati,et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. , 2003, Journal of the American College of Cardiology.
[129] C. Di Mario,et al. Stented segment length as an independent predictor of restenosis. , 1999, Journal of the American College of Cardiology.
[130] J. Ruiz-Nodar,et al. Direct coronary stenting versus stenting with balloon pre-dilation: immediate and follow-up results of a multicentre, prospective, randomized study. The DISCO trial. DIrect Stenting of COronary Arteries. , 2002, European heart journal.